MA55752A - Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies - Google Patents

Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies

Info

Publication number
MA55752A
MA55752A MA055752A MA55752A MA55752A MA 55752 A MA55752 A MA 55752A MA 055752 A MA055752 A MA 055752A MA 55752 A MA55752 A MA 55752A MA 55752 A MA55752 A MA 55752A
Authority
MA
Morocco
Prior art keywords
nephropathies
treatment
pharmaceutical compositions
new compounds
associated pharmaceutical
Prior art date
Application number
MA055752A
Other languages
English (en)
Inventor
Reginald Christophe Xavier Brys
Thierry Jean-Claude Marie Christophe
Katja Els Conrath
Der Geest Ronald Van
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MA55752A publication Critical patent/MA55752A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA055752A 2019-04-24 2020-04-21 Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies MA55752A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1905711.6A GB201905711D0 (en) 2019-04-24 2019-04-24 Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases

Publications (1)

Publication Number Publication Date
MA55752A true MA55752A (fr) 2022-03-02

Family

ID=66810218

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055752A MA55752A (fr) 2019-04-24 2020-04-21 Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies

Country Status (16)

Country Link
US (1) US12383544B2 (fr)
EP (1) EP3958863B1 (fr)
JP (1) JP7543304B2 (fr)
KR (1) KR20220004111A (fr)
CN (1) CN113727711A (fr)
AU (1) AU2020263869A1 (fr)
BR (1) BR112021021117A2 (fr)
CA (1) CA3137445A1 (fr)
ES (1) ES2982398T3 (fr)
GB (1) GB201905711D0 (fr)
IL (1) IL287392A (fr)
MA (1) MA55752A (fr)
MX (1) MX2021012544A (fr)
PH (1) PH12021552680A1 (fr)
SG (1) SG11202111739VA (fr)
WO (1) WO2020216740A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025096453A1 (fr) * 2023-10-30 2025-05-08 Vertex Pharmaceuticals Incorporated Composés pour le traitement d'une maladie rénale
WO2025121320A1 (fr) * 2023-12-04 2025-06-12 国立大学法人山口大学 Agent prophylactique ou thérapeutique contre la polykystose rénale
TW202547458A (zh) * 2024-03-26 2025-12-16 香港商禮邦醫藥（香港）有限公司 用於治療體染色體顯性多囊性腎病之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
US8362031B2 (en) 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
IN2012DN00719A (fr) * 2009-08-10 2015-06-19 Univ California
TWI633887B (zh) * 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及／或治療多囊性腎臟病之藥物
US10174012B2 (en) * 2014-11-04 2019-01-08 The University Of Kansas LKB1-AMPK activators for therapeutic use in polycystic kidney disease
JP2018530557A (ja) 2015-10-09 2018-10-18 アッヴィ・エス・ア・エール・エル 置換ピラゾロ［３，４−ｂ］ピリジン−６−カルボン酸およびこの使用
EP3359540A1 (fr) * 2015-10-09 2018-08-15 AbbVie S.À.R.L. Nouveaux composés destinés au traitement de la fibrose kystique
KR20180083323A (ko) * 2015-10-09 2018-07-20 애브비 에스.에이.알.엘. N-설포닐화 피라졸로[3,4-b]피리딘-6-카복스아미드 및 사용 방법
JP2020525446A (ja) * 2017-06-21 2020-08-27 ザ・ジョンズ・ホプキンス・ユニバーシティ 常染色体優性多発性嚢胞腎疾患を治療するための嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子

Also Published As

Publication number Publication date
MX2021012544A (es) 2021-11-12
CA3137445A1 (fr) 2020-10-29
ES2982398T3 (es) 2024-10-16
US20220202802A1 (en) 2022-06-30
JP7543304B2 (ja) 2024-09-02
CN113727711A (zh) 2021-11-30
PH12021552680A1 (en) 2022-07-04
BR112021021117A2 (pt) 2021-12-14
US12383544B2 (en) 2025-08-12
KR20220004111A (ko) 2022-01-11
JP2022529814A (ja) 2022-06-24
IL287392A (en) 2021-12-01
GB201905711D0 (en) 2019-06-05
EP3958863C0 (fr) 2024-07-03
EP3958863B1 (fr) 2024-07-03
WO2020216740A1 (fr) 2020-10-29
EP3958863A1 (fr) 2022-03-02
AU2020263869A1 (en) 2021-12-23
SG11202111739VA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA51739A (fr) Compositions pharmaceutiques pour le traitement de la fibrose kystique
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
EP3924481A4 (fr) Compositions et méthodes de traitement d'hémoglobinopathies
MA52118A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3890747A4 (fr) Compositions pour le traitement de la fibrose et de l'inflammation
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
MA55497A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires
EP3402533A4 (fr) Méthodes et compositions pour le traitement d'une maladie neurologique
EP3846830A4 (fr) Méthodes et compositions pour le traitement de maladie musculo-squelettiques
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
EP3841086A4 (fr) Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3762505A4 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3328864A4 (fr) Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
EP3661553A4 (fr) Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
EP3801478A4 (fr) Méthodes et compositions pour la prévention ou le traitement de la calciphylaxie
MA55752A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies
EP3935078A4 (fr) Compositions et méthodes pour le diagnostic et le traitement de rétinopathies